Medical devices, healthcare technology and the business of care
510(k) clearance · K261517

qCT Lung (v1.0)

Qure.Ai Technologies Pvt. , Ltd. · Decision date Sep 14, 2026

MEDTECHLEDGER EXPLANATIONK261517

What did the FDA decide?

FDA's records show a substantially equivalent (SESE) decision dated September 14, 2026 for qCT Lung (v1.0), submitted by Qure.Ai Technologies Pvt., Ltd. under K261517. The device is a Class II radiological computer-assisted detection and diagnosis software under 21 CFR 892.2090, product code QDQ, in the radiology specialty. The public database lists the application as a traditional 510(k) received May 7, 2026, with a predetermined change control plan authorized. SESE means clearance to market, not PMA approval.

The 510(k) summary describes an AI-based tool that processes non-contrast DICOM CT images to assist radiologists and pulmonologists in detecting, characterizing and quantifying pulmonary nodules, deployable on cloud or on-premises servers. The stated indication covers CT scans from a lung cancer screening population, with nodule size 4–30 mm, and describes the software as adjunctive rather than a replacement for physician review. The summary names Lunit INSIGHT DBT v1.1 (K242652) as predicate and ClearRead CT and Philips LNA as reference devices. Performance data and the content of the authorized change control plan are not in the supplied excerpts.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Sep 14, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261517
Regulatory pathway
510(k) premarket notification
Product code
QDQ
Decision code
SESE
Decision date
Sep 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer.

Product code
QDQ
FDA device class
2

FDA decision timeline

  1. K261517 received

    Application receipt date recorded by FDA.

  2. K261517 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QDQ

Product / regulatory recordCompanyPathwayDecision dateSource
CadAI-B DxK263749
BeamWorks, Inc.510(k) clearanceNov 6, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Qure.Ai Technologies Pvt. , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Mumbai

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records